5IML
| Nanobody targeting human Vsig4 in Spacegroup P212121 | Descriptor: | Nanobody, V-set and immunoglobulin domain-containing protein 4 | Authors: | Wen, Y. | Deposit date: | 2016-03-06 | Release date: | 2017-01-11 | Last modified: | 2024-10-16 | Method: | X-RAY DIFFRACTION (1.8 Å) | Cite: | Structural evaluation of a nanobody targeting complement receptor Vsig4 and its cross reactivity Immunobiology, 222, 2017
|
|
5IMM
| Nanobody targeting mouse Vsig4 in Spacegroup P212121 | Descriptor: | Nanobody, Protein Vsig4 | Authors: | Wen, Y, Zheng, F. | Deposit date: | 2016-03-06 | Release date: | 2017-01-11 | Last modified: | 2017-07-05 | Method: | X-RAY DIFFRACTION (1.2 Å) | Cite: | Structural evaluation of a nanobody targeting complement receptor Vsig4 and its cross reactivity Immunobiology, 222, 2017
|
|
5IR3
| |
5IUS
| Crystal structure of human PD-L1 in complex with high affinity PD-1 mutant | Descriptor: | CHLORIDE ION, Programmed cell death 1 ligand 1, Programmed cell death protein 1 | Authors: | Pascolutti, R, Sun, X, Kao, J, Maute, R, Ring, A.M, Bowman, G.R, Kruse, A.C. | Deposit date: | 2016-03-18 | Release date: | 2016-09-28 | Last modified: | 2023-09-27 | Method: | X-RAY DIFFRACTION (2.889 Å) | Cite: | Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant. Structure, 24, 2016
|
|
5J06
| Structure of the immune receptor CD33 in complex with 3'-sialyllactose | Descriptor: | 2-(2-METHOXYETHOXY)ETHANOL, 2-acetamido-2-deoxy-beta-D-glucopyranose, Myeloid cell surface antigen CD33, ... | Authors: | Dodd, R.B. | Deposit date: | 2016-03-27 | Release date: | 2017-04-05 | Last modified: | 2024-01-10 | Method: | X-RAY DIFFRACTION (2.66 Å) | Cite: | STRUCTURE OF LIGAND BOUND CD33 RECEPTOR ASSOCIATED WITH ALZHEIMER'S DISEASE To Be Published
|
|
5J0B
| Structure of the immune receptor CD33 in complex with 6'-sialyllactose | Descriptor: | 2-(2-METHOXYETHOXY)ETHANOL, 2-acetamido-2-deoxy-beta-D-glucopyranose, Myeloid cell surface antigen CD33, ... | Authors: | Dodd, R.B. | Deposit date: | 2016-03-28 | Release date: | 2017-04-05 | Last modified: | 2024-10-16 | Method: | X-RAY DIFFRACTION (2.48 Å) | Cite: | STRUCTURE OF LIGAND BOUND CD33 RECEPTOR ASSOCIATED WITH ALZHEIMER'S DISEASE To Be Published
|
|
5J89
| Structure of human Programmed cell death 1 ligand 1 (PD-L1) with low molecular mass inhibitor | Descriptor: | 1,2-ETHANEDIOL, N-{2-[({2-methoxy-6-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]pyridin-3-yl}methyl)amino]ethyl}acetamide, Programmed cell death 1 ligand 1 | Authors: | Zak, K.M, Grudnik, P, Guzik, K, Zieba, B.J, Musielak, B, Doemling, P, Dubin, G, Holak, T.A. | Deposit date: | 2016-04-07 | Release date: | 2016-04-27 | Last modified: | 2024-01-10 | Method: | X-RAY DIFFRACTION (2.2 Å) | Cite: | Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget, 7, 2016
|
|
5J8O
| Structure of human Programmed cell death 1 ligand 1 (PD-L1) with low molecular mass inhibitor | Descriptor: | (2R)-1-({3-bromo-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl}methyl)piperidine-2-carboxylic acid, Programmed cell death 1 ligand 1 | Authors: | Zak, K.M, Grudnik, P, Guzik, K, Zieba, B.J, Musielak, B, Doemling, P, Dubin, G, Holak, T.A. | Deposit date: | 2016-04-08 | Release date: | 2016-04-27 | Last modified: | 2024-10-09 | Method: | X-RAY DIFFRACTION (2.3 Å) | Cite: | Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget, 7, 2016
|
|
5JDR
| Structure of PD-L1 | Descriptor: | Programmed cell death 1 ligand 1 | Authors: | Zhou, A, Wei, H. | Deposit date: | 2016-04-17 | Release date: | 2017-04-12 | Last modified: | 2023-11-08 | Method: | X-RAY DIFFRACTION (2.7 Å) | Cite: | Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade. Cell Discov, 3, 2017
|
|
5JDS
| |
5JXE
| Human PD-1 ectodomain complexed with Pembrolizumab Fab | Descriptor: | Pembrolizumab Fab heavy chain, Pembrolizumab Fab light chain, Programmed cell death protein 1 | Authors: | Na, Z, Bharath, S.R, Song, H. | Deposit date: | 2016-05-13 | Release date: | 2016-08-10 | Last modified: | 2023-11-08 | Method: | X-RAY DIFFRACTION (2.9 Å) | Cite: | Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab. Cell Res., 27, 2017
|
|
5L8L
| |
5L8K
| |
5L8J
| |
5B8C
| High resolution structure of the human PD-1 in complex with pembrolizumab Fv | Descriptor: | Pembrolizumab heavy chain variable region (PemVH), Pembrolizumab light chain variable region (PemVL), Programmed cell death protein 1 | Authors: | Horita, S, Shimamura, T, Iwata, S, Nomura, N. | Deposit date: | 2016-06-14 | Release date: | 2016-10-26 | Last modified: | 2023-11-08 | Method: | X-RAY DIFFRACTION (2.146 Å) | Cite: | High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1 Sci Rep, 6, 2016
|
|
5GGV
| CTLA-4 in complex with tremelimumab Fab | Descriptor: | Cytotoxic T-lymphocyte protein 4, heavy chain, light chain | Authors: | Heo, Y.S. | Deposit date: | 2016-06-16 | Release date: | 2016-11-09 | Last modified: | 2016-11-16 | Method: | X-RAY DIFFRACTION (1.998 Å) | Cite: | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy Nat Commun, 7, 2016
|
|
5GGR
| PD-1 in complex with nivolumab Fab | Descriptor: | Programmed cell death protein 1, heavy chain, light chain | Authors: | Heo, Y.S. | Deposit date: | 2016-06-16 | Release date: | 2016-11-09 | Last modified: | 2016-11-16 | Method: | X-RAY DIFFRACTION (3.3 Å) | Cite: | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy Nat Commun, 7, 2016
|
|
5GGT
| PD-L1 in complex with BMS-936559 Fab | Descriptor: | IGK@ protein, IgG H chain, Programmed cell death 1 ligand 1 | Authors: | Heo, Y.S. | Deposit date: | 2016-06-16 | Release date: | 2016-11-09 | Last modified: | 2024-03-20 | Method: | X-RAY DIFFRACTION (2.8 Å) | Cite: | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy Nat Commun, 7, 2016
|
|
5GGS
| PD-1 in complex with pembrolizumab Fab | Descriptor: | Programmed cell death protein 1, heavy chain, light chain | Authors: | Heo, Y.S. | Deposit date: | 2016-06-16 | Release date: | 2016-11-09 | Last modified: | 2016-11-16 | Method: | X-RAY DIFFRACTION (1.997 Å) | Cite: | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy Nat Commun, 7, 2016
|
|
5KSB
| T15-DQ8.5-glia-gamma1 complex | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, DQ8.5-glia-gamma1 peptide, ... | Authors: | Petersen, J, Rossjohn, J, Reid, H.H. | Deposit date: | 2016-07-08 | Release date: | 2016-09-21 | Last modified: | 2020-07-29 | Method: | X-RAY DIFFRACTION (2.9 Å) | Cite: | Diverse T Cell Receptor Gene Usage in HLA-DQ8-Associated Celiac Disease Converges into a Consensus Binding Solution. Structure, 24, 2016
|
|
5KS9
| Bel502-DQ8-glia-alpha1 complex | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Bel502 TCR alpha TRAV20*01, Bel502 TCR beta TRBV9*01, ... | Authors: | Petersen, J, Rossjohn, J, Reid, H.H. | Deposit date: | 2016-07-08 | Release date: | 2016-09-21 | Last modified: | 2020-07-29 | Method: | X-RAY DIFFRACTION (2.55 Å) | Cite: | Diverse T Cell Receptor Gene Usage in HLA-DQ8-Associated Celiac Disease Converges into a Consensus Binding Solution. Structure, 24, 2016
|
|
5KSA
| Bel602-DQ8.5-glia-gamma1 complex | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Bel602 alpha TRAV20*01, Bel602 beta TRBV9*01, ... | Authors: | Petersen, J, Rossjohn, J, Reid, H.H. | Deposit date: | 2016-07-08 | Release date: | 2016-09-21 | Last modified: | 2020-07-29 | Method: | X-RAY DIFFRACTION (2 Å) | Cite: | Diverse T Cell Receptor Gene Usage in HLA-DQ8-Associated Celiac Disease Converges into a Consensus Binding Solution. Structure, 24, 2016
|
|
5GRJ
| Crystal structure of human PD-L1 with monoclonal antibody avelumab | Descriptor: | Programmed cell death 1 ligand 1, avelumab H chain, avelumab L chain | Authors: | Liu, K, Tan, S, Chai, Y, Chen, D, Song, H, Zhang, C.W.-H, Shi, Y, Liu, J, Tan, W, Lyu, J, Gao, S, Yan, J, Qi, J, Gao, G.F. | Deposit date: | 2016-08-11 | Release date: | 2016-11-02 | Last modified: | 2023-11-08 | Method: | X-RAY DIFFRACTION (3.206 Å) | Cite: | Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy. Cell Res., 27, 2017
|
|
5M00
| Crystal structure of murine P14 TCR complex with H-2Db and Y4A, modified gp33 peptide from LCMV | Descriptor: | Beta-2-microglobulin, H-2 class I histocompatibility antigen, D-B alpha chain, ... | Authors: | Achour, A, Sandalova, T, Sun, R, Han, X. | Deposit date: | 2016-10-03 | Release date: | 2017-12-20 | Last modified: | 2024-01-17 | Method: | X-RAY DIFFRACTION (1.95 Å) | Cite: | Thernary complexes of TCR P14 give insights into the mechanisms behind reestablishment of CTL responses against a viral escape mutant To Be Published
|
|
5M01
| Crystal structure of murine P14 TCR/ H-2Db complex with PA, modified gp33 peptide from LCMV | Descriptor: | Beta-2-microglobulin, GLYCEROL, H-2 class I histocompatibility antigen, ... | Authors: | Achour, A, Sandalova, T, Sun, R, Han, X. | Deposit date: | 2016-10-03 | Release date: | 2017-10-25 | Last modified: | 2024-01-17 | Method: | X-RAY DIFFRACTION (1.95 Å) | Cite: | Thernary complexes of TCR P14 give insights into the mechanisms behind reestablishment of CTL responses against a viral escape mutant To Be Published
|
|